Percent I-131 uptake and post-therapy I-131 scans: Their role in the management of thyroid cancer

被引:30
作者
Reynolds, JC
机构
[1] Nuclear Medicine Department, National Institutes of Health, Bethesda
[2] Nuclear Medicine Department, National Institutes of Health, Bldg. 10, Bethesda, MD 20892
关键词
D O I
10.1089/thy.1997.7.281
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This short review focuses on two questions commonly asked about I-131 therapy of thyroid cancer. The first relates to radiation dosimetry. What percentage of I-131 uptake is needed for effective therapy? Studies have shown that I-131 uptake and therapeutic outcome may not be closely related. A more powerful relationship, however, occurs by using percent uptake per gram. A rearrangement of the basic dosimetry equation shows that for a specific level of radiation, percent uptake per gram and effective half-life are inversely related. Formulas developed from this relationship are useful in determining whether uptake is satisfactory but require estimates of effective half-life and tumor mass. The second question is whether post-therapy I-131 scans are useful. Because the sensitivity of I-131 scanning is related directly to the amount of radioactivity administered, imaging after therapy may show previously undetected lesions that not infrequently are distant metastases. Thus, information from post-therapy scans may 1) after therapy, 2) direct new diagnostic studies, 3) lead to formal dosimetry studies when maximal I-131 doses are needed to treat distant metastases, and 4) be necessary to obtain when I-131 therapy is administered to patients with elevated thyroglobulin and negative diagnostic scans. Should post-therapy scans always be performed? They are easy to perform and are clinically useful but may be inconvenient to patients and costly overall. At this time, however, there is not a simple paradigm for selecting patients who may forego these scans.
引用
收藏
页码:281 / 284
页数:4
相关论文
共 13 条
[1]  
ARNSTEIN NB, 1986, J NUCL MED, V27, P1764
[2]  
BALACHANDRAN S, 1981, Clinical Nuclear Medicine, V6, P162, DOI 10.1097/00003072-198104000-00006
[3]   THE DIAGNOSTIC AND THERAPEUTIC VALUE OF THYROTROPIC HORMONE AND HEAVY DOSAGE SCINTIGRAMS FOR THE DEMONSTRATION OF THYROID CANCER METASTASES [J].
CATZ, B ;
PETIT, D ;
STARR, P .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1959, 237 (02) :158-164
[4]  
MAXON HR, 1992, J NUCL MED, V33, P1132
[5]   RELATION BETWEEN EFFECTIVE RADIATION-DOSE AND OUTCOME OF RADIOIODINE THERAPY FOR THYROID-CANCER [J].
MAXON, HR ;
THOMAS, SR ;
HERTZBERG, VS ;
KEREIAKES, JG ;
CHEN, IW ;
SPERLING, MI ;
SAENGER, EL .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (16) :937-941
[6]  
MAXON HR, 1991, J NUCL MED, V32, pP295
[7]  
NEMEC J, 1979, J NUCL MED, V20, P92
[8]   I-131 THERAPY FOR THYROID-CANCER PATIENTS WITH ELEVATED THYROGLOBULIN AND NEGATIVE DIAGNOSTIC SCAN [J].
PINEDA, JD ;
LEE, T ;
AIN, K ;
REYNOLDS, JC ;
ROBBINS, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (05) :1488-1492
[9]  
QUIMBY EH, 1970, RADIOACTIVE NUCLIDES, P114
[10]   RADIATION-DOSE ASSESSMENTS IN RADIOIODINE (I-131) THERAPY .1. THE NECESSITY FOR INVIVO QUANTITATION AND DOSIMETRY IN THE TREATMENT OF CARCINOMA OF THE THYROID [J].
SCHLESINGER, T ;
FLOWER, MA ;
MCCREADY, VR .
RADIOTHERAPY AND ONCOLOGY, 1989, 14 (01) :35-41